Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2025 09:00 ET | Source: Janssen Cilag International NV

European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in infusion-related reactions compared to the IV...
April 07, 2025 05:32 ET | Source: Janssen Cilag International NV

European Commission approves Johnson & Johnson’s subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting Phase 3 CEPHEUS study shows...
March 28, 2025 10:05 ET | Source: Janssen Cilag International NV

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) zeigt einen signifikanten Gesamtüberlebensvorteil bei Patienten mit EGFR-mutiertem fortgeschrittenem nicht-kleinzelligem Lungenkrebs im Vergleich zu osimertinib

Das mediane Gesamtüberleben wurde noch nicht erreicht, mit einer prognostizierten Verbesserung von mehr als einem Jahr gegenüber osimertinib*1 BEERSE, BELGIEN, March 28, 2025 (GLOBE NEWSWIRE) --...
March 28, 2025 09:57 ET | Source: Janssen Cilag International NV

L’association RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) démontre un bénéfice significatif en termes de survie globale chez les patients atteints d’un cancer du poumon non à petites cellules avancé muté par l’EGFR par rapport à l’osimertinib

La survie globale médiane n’a pas encore été atteinte avec une amélioration prévue de plus d’un an par rapport à l’osimertinib*1 BEERSE, BELGIQUE, 28 mars 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag...
March 28, 2025 07:20 ET | Source: Janssen Cilag International NV

TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the...
March 26, 2025 11:50 ET | Source: Janssen Cilag International NV

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) demonstrates significant overall survival benefit in patients with EGFR-mutated advanced non-small cell lung cancer versus osimertinib

Median overall survival not yet reached with a projected improvement of more than one year versus osimertinib*1BEERSE, BELGIUM, March 26, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a...
March 03, 2025 10:58 ET | Source: Janssen Cilag International NV

Le schéma thérapeutique à base de DARZALEX® (daratumumab) par voie sous-cutanée de Johnson & Johnson reçoit un avis favorable du CMUH pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, quelle que soit l’éligibilité à la greffe

S’il est approuvé, le daratumumab sera le seul anti-CD38 disponible pour tous les types de patients atteints d’un myélome multiple nouvellement diagnostiqué, faisant ainsi du daratumumab un traitement...
February 28, 2025 08:43 ET | Source: Janssen Cilag International NV

TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis1 Beerse, Belgium (28 February 2025) – Johnson & Johnson today announced that the Committee for...
February 28, 2025 08:01 ET | Source: Janssen Cilag International NV

Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab as a foundational therapy in the frontline setting. ...
February 07, 2025 12:43 ET | Source: Janssen Cilag International NV

CHMP empfiehlt subkutane Verabreichung von RYBREVANT®▼ (amivantamab) zur Behandlung von Patienten mit fortgeschrittenem EGFR-mutiertem nicht-kleinzelligem Lungenkrebs

Die Daten der Phase-III-Studie PALOMA-3 zeigten eine Nichtunterlegenheit gegenüber der intravenösen Verabreichung bei beiden primären pharmakokinetischen (PK) Endpunkten sowie eine fünffache Reduktion...